Track LL-37 in Peptimes
LL-37 is a peptide: a chain of 37 amino acids, also called cathelicidin LL-37. FDA's substance registry lists it as ropocamptide. (Source: FDA's substance registry (GSRS).)
Is LL-37 FDA-approved?
No. LL-37 (ropocamptide) isn't FDA-approved, and Drugs@FDA lists no application with it as an active ingredient.
LL-37
Also: cathelicidin LL-37, CAMP peptide, ropocamptide
- Status label in the Peptimes Library
- Not FDA-Approved
- Routes in Peptimes
- SubcutaneousTopical
- Updated
- 25 Oct 2026
US regulatory status
FDA status
Not FDA-Approved. Drugs@FDA lists no application with LL-37 (ropocamptide) as an active ingredient.
Source: Drugs@FDA, checked 25 Oct 2026
How to track it in Peptimes
Add LL-37 in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Not FDA-Approved”.
- Routes: subcutaneous or topical. Choose the one that matches each dose.
- Logging: the amount you took, the route and how you feel.
- Injection sites: subcutaneous doses record the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next. Topical doses skip this step.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell LL-37 or any other compound.
More sources
- FDA, Global Substance Registration System, Ropocamptide, checked 25 Oct 2026: its sequence of 37 amino acids, and the names LL-37, cathelicidin LL-37 and ropocamptide.
Related pages
Coming soon to the App Store
See planned pricing